FOLR1 is an inclusion criterion in 6 clinical trials for fallopian tube carcinoma, of which 6 are open and 0 are closed. Of the trials that contain FOLR1 status and fallopian tube carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].

FOLR1 is an inclusion criterion in 6 clinical trials for primary peritoneal carcinoma, of which 6 are open and 0 are closed. Of the trials that contain FOLR1 status and primary peritoneal carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].

FOLR1 is an inclusion criterion in 5 clinical trials for ovarian carcinoma, of which 5 are open and 0 are closed. Of the trials that contain FOLR1 status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].

FOLR1 is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 2 are open and 2 are closed. Of the trials that contain FOLR1 status and malignant solid tumor as inclusion criteria, 4 are phase 1 (2 open) [4].

FOLR1 is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 1 is open and 2 are closed. Of the trials that contain FOLR1 status and breast carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (0 open) [4].

FOLR1 is an inclusion criterion in 2 clinical trials for endometrial serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain FOLR1 status and endometrial serous adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

FOLR1 is an inclusion criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain FOLR1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [4].

FOLR1 is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FOLR1 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) [4].

FOLR1 is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FOLR1 status and endometrial adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FOLR1 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FOLR1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FOLR1 is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FOLR1 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FOLR1 is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FOLR1 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

FOLR1 is an inclusion criterion in 1 clinical trial for ovarian carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FOLR1 status and ovarian carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FOLR1 is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FOLR1 status and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

FOLR1 is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FOLR1 status and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].